A comprehensive review of efficacy data on combination therapy with ADT and the AR inhibitor apalutamide in patients with mCSPC.
Gordon A. Brown, DO
Advertisement
Articles by Gordon A. Brown, DO
Dr Gordon Brown provides an overview of single-agent androgen deprivation therapy (ADT) and other regimens that may be used in combination with ADT, including androgen receptor (AR) inhibitors, for treatment of mCSPC.
An expert comments on the patient profile and offers insights into how he approaches treatment and management of prostate cancer.
Gordon A. Brown, DO, presents the profile of a 60-year-old man with prostate cancer.
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5